Skip to content

Aclaris Therapeutics, Inc.

ACRS

CIK 0001557746

← back to feed
Revenue (TTM)
$8.53M
−58.2% YoY Q1 Apr 2026
Net Income (TTM)
−$64.95M
+50.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.52
+69.0% YoY Q1 Apr 2026
Gross Margin
38.8%
Q1 Apr 2026
Operating Margin
-889.3%
Q1 Apr 2026
Net Margin
-761.7%
Q1 Apr 2026
Free Cash Flow (TTM)
−$79.12M
Q1 Apr 2026
Cash
$28.66M
Q1 Apr 2026
Total Debt
$10.73M
Q1 Apr 2026
Shares Outstanding
139.66M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings